Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Conclusion/summary: This first proof of principle study demonstrates the feasibility of the combination of pembrolizumab and decitabine in relapsed/refractory adult AML patients..Table.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Lindblad, K. E., Thompson, J., Gui, G., Valdez, J., Worthy, T., Tekleab, H., Hughes, T., Goswami, M., Oetjen, K., Kim, D.-Y., Dillon, L., DeStefano, C., Lai, C. E., Hourigan, C. S. Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I Source Type: research